Carbinoxamine
Clinical data
Trade namesClistin, others
AHFS/Drugs.comMonograph
MedlinePlusa606008
Pregnancy
category
  • C
Routes of
administration		Oral: 4 mg tablet or 4 mg/5 mL liquid
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life10 to 20 hours
Identifiers
  • 2-[(4-Chlorophenyl)-pyridin-2-yl-methoxy]-N,N-
    dimethyl-ethanamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.006.935
Chemical and physical data
FormulaC16H19ClN2O
Molar mass290.79 g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1)C(OCCN(C)C)c2ncccc2
  • InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3 checkY
  • Key:OJFSXZCBGQGRNV-UHFFFAOYSA-N checkY
  (verify)

Carbinoxamine is an antihistamine and anticholinergic agent. It is used for hay fever, vasomotor rhinitis, mild urticaria, angioedema, dermatographism and allergic conjunctivitis. Carbinoxamine is a histamine antagonist, specifically an H1-antagonist. The maleic acid salt of the levorotatory isomer is sold as the prescription drug rotoxamine.

It was patented in 1947 and came into medical use in 1953.[1] It was first launched in the United States by the McNeil Corporation under the brand name Clistin. Carbinoxamine is available in various countries around the world by itself, combined with decongestants such as pseudoephedrine, and also with other ingredients including paracetamol, aspirin, and codeine.

Society and culture

In June 2006 the FDA announced that more than 120 branded pharmacy products containing carbinoxamine were being illegally marketed and demanded they be removed from the marketplace. This action was precipitated by twenty-one reported deaths in children under the age of two who had been administered carbinoxamine-containing products. Despite the fact that the drug had not been studied in this age group, a multitude of OTC preparations containing carbinoxamine were being marketed for infants and toddlers. At present, all carbinoxamine-containing formulations are approved only for adults or children ages 3 or older.[2]

Brand names

Brand names include Clistin, Palgic, Rondec, Rhinopront, Ryvent.

Side effects

Continuous and/or cumulative use of anticholinergic medication, including first-generation antihistamines, is associated with a higher risk of cognitive decline and dementia in older people.[3][4]

See also

References

  1. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 545. ISBN 9783527607495.
  2. ↑ "Questions and Answers about Unapproved Drugs and FDA's Enforcement Action Against Carbinoxamine Products" (PDF). U.S. Food and Drug Administration. Archived from the original (PDF) on 7 March 2016.
  3. ↑ Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. (March 2015). "Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study". JAMA Internal Medicine. 175 (3): 401–407. doi:10.1001/jamainternmed.2014.7663. PMC 4358759. PMID 25621434.
  4. ↑ Carrière I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, Ancelin ML (July 2009). "Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study". Archives of Internal Medicine. 169 (14): 1317–1324. doi:10.1001/archinternmed.2009.229. PMC 2933398. PMID 19636034.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.